Bluejay Diagnostics, Inc. (BJDX) Fair Value 2026

BJDX · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 6 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-07-13, Bluejay Diagnostics, Inc. (BJDX) trades at $1.22, approximately 46% below CirclFi’s Bayesian DCF fair value of $2.27. QOC: 4.1/10. Value Trap Risk: 33/100 (LOW). 6/13 models active.

Key Facts

Ticker
BJDX
Price
$1.22
Quality Score
4.1/10
Value Trap Risk
33/100
Models Active
6/13
Last Updated
Strength: CUCE Ensemble suggests +252.5% upside with 3% confidence
Risk: Below-average Quality Score of 4.1/10 signals weak fundamentals

Valuation Matrix

6 Intrinsic Value Models vs. Current Price ($1.22)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$2.27 +86.3%
CUCE Ensemble
Low Conviction
$4.30 +252.5%
First Chicago
Low Conviction
$3.48 +185.3%

Unlock the Full Matrix

Access 3 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is Bluejay Diagnostics, Inc. (BJDX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bluejay Diagnostics, Inc. is potentially undervalued at its current price of $1.22. Based on our 13-model framework, Bluejay Diagnostics, Inc.'s intrinsic value is estimated at a composite fair value of $2.58 — representing +111.3% implied upside — with 5 out of 6 active models confirming this thesis. Model dispersion is worth noting: CUCE targets $4.30 (+252.5%), versus ML-RIV at $0.52 (-57.2%). This +309.7% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BJDX?

6 of 13 models are currently active for BJDX. Of these, 5 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates BJDX's intrinsic value at $2.27, implying +86.3% upside from the current price. See which stocks rank higher →

How Does BJDX Rank in Surgical & Medical Instruments & Apparatus?

Among 111 Surgical & Medical Instruments & Apparatus stocks, BJDX ranks #101 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

Bluejay Diagnostics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BJDX a Value Trap?

CirclFi's Value Trap algorithm assigns BJDX a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Bluejay Diagnostics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bluejay Diagnostics, Inc. earns a quality score of 4.1/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +309.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BJDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BJDX's 6 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bluejay Diagnostics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About Bluejay Diagnostics, Inc.

What is Bluejay Diagnostics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Bluejay Diagnostics, Inc. (BJDX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $2.27. The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BJDX overvalued or undervalued right now?

At $1.22, 5 of 6 active models suggest BJDX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Bluejay Diagnostics, Inc.'s business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 4.1 mean for BJDX?

Bluejay Diagnostics, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BJDX?

CirclFi analyzes BJDX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Is BJDX a value trap in 2026?

Bluejay Diagnostics, Inc.'s Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on BJDX.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access